ArticlePakistan journal of medical sciences2025
Clinical efficacy and safety of antibiotic combination therapy in the treatment of community-acquired pneumonia in children.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine the efficacy and safety of cefotaxime combined with azithromycin in the treatment of children with community-acquired pneumonia (CAP) and its effect on inflammatory factors. Methods: This is an observational study. A total of 118 children with CAP admitted to our hospital from June, 2022 to December, 2023 were randomly selected. According to the random number table method, they were divided into a control group and a combination treatment group, with 59 children in each group. The children in the control group were treated with azithromycin, and those in the combination treatment group were treated with cefotaxime combined with azithromycin. Both groups were treated for a week. The disappearance time of symptoms (fever, pulmonary rales, cough) and the improvement of inflammatory indicators (serum interleukin-6 (IL-6), serum C-reactive protein (CRP), and serum interleukin-8 (IL-8)) after treatment were compared. The clinical efficacy and adverse reactions were compared between the two groups. Results: The disappearance time of fever, pulmonary rales, and cough in the combination treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the serum levels of CRP, IL-6, and IL-8 in the two groups were lower than those before treatment, and the reduction in the combination treatment group was larger than that in the control group (P < 0.05). The total efficacy of the combination treatment group was significantly higher than that of the control group (P < 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Cefotaxime combined with azithromycin in the treatment of CAP in children can significantly improve the efficacy, quickly relieve clinical symptoms, improve the body's defense mechanism, inhibit inflammatory response, and has high safety, which is worthy of clinical promotion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.